Contents    Cover    Publication Date: 25.06.2019
Year 2019 - Volume 29 - Issue 2

Comparison of the Immunohistochemical Staining of Lumican in Endometrioid-Type Endometrial Cancer and Endometrial Intraepithelial Neoplasias

Full Text PDF  
JCOG 2019;29(2):50-6
DOI: 10.5336/jcog.2019-64952
Article Language: EN
147 Viewed -- 110 Downloaded
Objective: This study aimed to evaluate the significance and correlation of immunohistochemical staining of lumican, an extracellular matrix proteoglycan, with the clinicopathological parameters in endometrial intraepithelial neoplasia (EIN) and endometrioid-type endometrial cancer (ETEC). Material and Methods: This cross-sectional study was carried out together in the obstetrics & gynecology and pathology departments of a tertiary care center. A total of 46 patients with EIN (n=19; 41.3%) and ETEC (n=27; 58.7%) were recruited for the study. Sections prepared from hysterectomy specimens of the patients were immunohistochemically processed and examined for immunohistochemical staining of lumican. The positive association between immunohistochemical staining of lumican and its relationship with clinicopathological variables were then investigated. Results: Lumican staining was more prominent in specimens obtained from ETEC patients as compared to that obtained from patients with EIN (p>0.01). The patients in the ETEC group were significantly elder than those in the EIN group (p=0.01). No statistically significant association was found between the lumican positivity and the histopathological parameters including grade; stage; squamous differentiation; lymph node metastases; myometrial, cervical, adnexial or omental invasion; and pelvic or paraaortic lymph node involvement. Conclusion: The study concluded that elucidation of the molecular basis underlying endometrial cancer may allow the recognition of novel molecular targets for diagnostic and therapeutic strategies of cancers of the endometrium. However, the importance of immunohistochemical staining and clinicopathological significance of lumican in endometrial cancer needs to be further studied by multicentric studies in larger numbers.
  1. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008;108(3-5):221-9. [Crossref] [PubMed]
  2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7. [Crossref]
  3. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8-13. [Crossref] [PubMed]
  4. Semere LG, Ko E, Johnson NR, Vitonis AF, Phang LJ, Cramer DW, et al. Endometrial intraepithelial neoplasia: clinical correlates and outcomes. Obstet Gynecol. 2011;118(1):21-8.[Crossref] [PubMed] [PMC]
  5. Rosato A, Menin C, Boldrin D, Dalla Santa S, Bonaldi L, Scaini MC, et al. Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer. 2013;79(2):180-6. [Crossref] [PubMed]
  6. Cappellesso R, Tinazzi A, Giurici T, Simonato F, Guzzardo V, Ventura L, et al. Programmed cell death 4 and micro RNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014;122(9):685-93. [Crossref] [PubMed]
  7. Cappellesso R, Millioni R, Arrigoni G, Simonato F, Caroccia B, Iori E, et al. Lumican is overexpressed in lung adenocarcinoma pleural effusions. PLoS One. 2015;10(5): e0126458. [Crossref] [PubMed] [PMC]
  8. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res. 2004;3(2):179-96. [Crossref]
  9. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24(8):971-83. [Crossref] [PubMed]
  10. Seya T, Tanaka N, Shinji S, Yokoi K, Koizumi M, Teranishi N, et al. Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncol Rep. 2006;16(6):1225-30. [Crossref] [PubMed]
  11. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 2011;15(5):1013-31. [Crossref] [PubMed] [PMC]
  12. Nikitovic D, Papoutsidakis A, Karamanos NK, Tzanakakis GN. Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response. Matrix Biol. 2014;35:206-14. [Crossref] [PubMed]
  13. Dolhnikoff M, Morin J, Roughley PJ, Ludwig MS. Expression of lumican in human lungs. Am J Respir Cell Mol Biol. 1998;19(4):582-7.[Crossref] [PubMed]
  14. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem. 2008;283(31):21305-9. [Crossref] [PubMed] [PMC]
  15. Stamov DR, Müller A, Wegrowski Y, Brezillon S, Franz CM. Quantitative analysis of type I collagen fibril regulation by lumican and decorin using AFM. J Struct Biol. 2013;183(3): 394-403. [Crossref] [PubMed]
  16. Vuillermoz B, Khoruzhenko A, D?Onofrio MF, Ramont L, Venteo L, Perreau C, et al. The small leucine rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res. 2004;296(2):294-306. [Crossref] [PubMed]
  17. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395-406. [Crossref] [PubMed] [PMC]
  18. Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y, et al. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. Int J Oncol. 2008;33(6):1177-85.
  19. Yamanaka O, Yuan Y, Coulson-Thomas VJ, Gesteira TF, Call MK, Zhang Y, et al. Lumican binds ALK5 to promote epithelium wound healing. PLoS One. 2013;8(12):e82730.[Crossref] [PubMed] [PMC]
  20. Ishiwata T, Cho K, Kawahara K, Yamamoto T, Fujiwara Y, Uchida E, et al. Role of lumican in cancer cells and adjacent stromal tissues in human pancreatic cancer. Oncol Rep. 2007;18(3):537-43. [Crossref] [PubMed]
  21. Naito Z, Ishiwata T, Kurban G, Teduka K, Kawamoto Y, Kawahara K, et al. Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests. Int J Oncol. 2002;20(5):943-8. [Crossref] [PubMed]